(NASDAQ: LIVN) Livanova's forecast annual revenue growth rate of 6.65% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.25%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.58%.
Livanova's revenue in 2026 is $1,471,519,000.On average, 13 Wall Street analysts forecast LIVN's revenue for 2026 to be $85,505,122,864, with the lowest LIVN revenue forecast at $81,097,642,304, and the highest LIVN revenue forecast at $88,590,359,256. On average, 13 Wall Street analysts forecast LIVN's revenue for 2027 to be $91,620,502,141, with the lowest LIVN revenue forecast at $86,331,525,469, and the highest LIVN revenue forecast at $96,854,385,306.
In 2028, LIVN is forecast to generate $98,507,190,516 in revenue, with the lowest revenue forecast at $91,014,473,564 and the highest revenue forecast at $108,313,834,762.